Comparative Pharmacology
Head-to-head clinical analysis: AMANTADINE versus LIVTENCITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMANTADINE versus LIVTENCITY.
AMANTADINE vs LIVTENCITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.
LIVTENCITY (maribavir) is an inhibitor of the human cytomegalovirus (CMV) UL97 protein kinase, which is essential for viral DNA replication, encapsidation, and egress of mature virions from the infected cell. By blocking UL97 kinase activity, maribavir inhibits viral replication.
100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).
200 mg orally once daily with food.
None Documented
None Documented
Clinical Note
moderateAmantadine + Haloperidol
"The therapeutic efficacy of Haloperidol can be decreased when used in combination with Amantadine."
Clinical Note
moderateAmantadine + Mifepristone
"Amantadine may increase the QTc-prolonging activities of Mifepristone."
Clinical Note
moderateAmantadine + Promazine
"The therapeutic efficacy of Promazine can be decreased when used in combination with Amantadine."
Clinical Note
moderateAmantadine + Chlorpromazine
Terminal elimination half-life: 10-14 hours in young adults, up to 24 hours in elderly; prolonged to >24 hours in renal impairment
Terminal elimination half-life is approximately 20 hours, supporting once-daily dosing for sustained antiviral activity.
Renal: 90% as unchanged drug via glomerular filtration and tubular secretion; fecal: <10%
Primarily hepatobiliary excretion; unchanged drug and metabolites eliminated in feces (86%) and urine (14%).
Category C
Category C
Antiviral / Antiparkinsonian
Antiviral
"The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Amantadine."